{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Yttrium_Y-90_Tacatuzumab_Tetraxetan",
  "nciThesaurus": {
    "casRegistry": "476413-07-7",
    "chebiId": "",
    "chemicalFormula": "C16H25N5O7.Y",
    "definition": "A radioimmunoconjugate comprised of the humanized monoclonal antibody tacatuzumab, directed against alpha fetoprotein, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 tacatuzumab tetraxetan binds to tumor cells expressing alpha fetoprotein, thereby selectively delivering a cytotoxic dose of beta radiation.",
    "fdaUniiCode": "GJ2416WK6Y",
    "identifier": "C48428",
    "preferredName": "Yttrium Y-90 Tacatuzumab Tetraxetan",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129819",
      "C1511"
    ],
    "synonyms": [
      "AFP-Cide",
      "Y-90 hAFP-31",
      "YTTRIUM Y-90 TACATUZUMAB TETRAXETAN",
      "Yttrium (90Y) Tacatuzumab Tetraxetan",
      "Yttrium Y 90 DOTA Monoclonal Antibody HuAFP31",
      "Yttrium Y 90 Tacatuzumab Tetraxetan",
      "Yttrium Y-90 Tacatuzumab Tetraxetan",
      "yttrium Y 90 DOTA monoclonal antibody HuAFP31"
    ]
  }
}